Page 1 of 1 IDS - 05/23/2006 SERIAL NO. 09/854,356 **FORM PTO-1449** INFORMATION DISCLOSURE STATEMENT **FILING DATE** May 9, 2001 APPLICANT Cheever 1642 **GROUP** Misook Yu **EXAMINER** ATTORNEY DOCKET NO. CRX113US1 U.S. PATENT DOCUMENTS Filing Date If Appropriate Examiner Patent **Issue Date** Name Class Subclass Initials Number 4,803,072 LAB. 1. 2/7/1989 Dalton et al. 5,723,130 3/3/1998 Hancock et al. 2. Cheever et al. 3. 5,726,023 3/10/1998 9/1/1998 Cheever et al. 4. 5,801,005 9/22/1998 Plowman et al. 5,811,098 5,846,538 12/8/1998 Cheever et al. 6. 3/2/1999 Cheever et al. 7. 5,876,712 8. 5,962,428 10/5/1999 Carrano et al. 9. 6,080,409 6/27/2000 Laus et al. Raychaudhuri et al. 10. 6,270,769 8/7/2001 9/11/2001 Kipps et al. 11. 6,287,569 Krieg et al. 12. 6,429,199 8/6/2002 Cheever et al. 13. 6,664,370 12/16/2003 6,734,172 5/11/2004 Scholler et al. 14. 9/13/2005 Cheever et al. 15. 6,942,862 16. 6,953,573 10/11/2005 Cheever et al. 7,005,498 2/28/2006 Steinaa et al. 17. 2002/018766 2/14/2002 Roberts et al. 18. FOREIGN PATENT DOCUMENTS Translation Document Publication | No Yes Number **Country** Class Subclass Date LAH 2/3/2000 PCT 19. WO00/04927 PCT 20. WO00/20027 4/13/2000 21. WO00/29582 5/25/2000 **PCT** WO98/25574 8/18/1998 PCT 22. PCT WO99/57981 11/18/1999 23. OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) 24. Disis - Abstract 2709; Abstracts from Meetings in New Orleans, June 2-6, 1996, The FASEB Journal, LAB 10(6):A1470 (1996). DERMER, Another Anniversary for the War on Cancer, Bio/Technology 12:320 (1994). 25. 26. SPITLER, Cancer Vaccines: The Interferon Analogy, Cancer Biotherapy 10(1):1-3 (1995). OSBAND and ROSS, Problems in Investigational Study and Clinical Use of Cancer Immunotherapy, 27. Immunology Today 1(6):193-195 (1990). DATE CONSIDERED **EXAMINER** 07/24/200b

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

/Lynn Bristol/